Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2026-01-01 @ 1:36 PM
Study NCT ID:
NCT03797456
Status:
COMPLETED
Last Update Posted:
2024-04-18
First Post:
2019-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-04-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-06
Completion Date Type:
ACTUAL
First Submit Date:
2019-01-07
First Submit QC Date:
None
Study First Post Date:
2019-01-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-17
Last Update Post Date:
2024-04-18
Last Update Post Date Type:
ACTUAL